PMC:7306567 / 2926-3045 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"46","span":{"begin":102,"end":111},"obj":"Chemical"}],"attributes":[{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:C551803"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T18","span":{"begin":113,"end":117},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"}],"text":"With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T9","span":{"begin":102,"end":111},"obj":"Chemical"}],"attributes":[{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_76612"}],"text":"With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T22","span":{"begin":0,"end":119},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T34","span":{"begin":102,"end":111},"obj":"CHEBI:76612;CHEBI:76612"},{"id":"T80755","span":{"begin":102,"end":111},"obj":"CHEBI:76612;CHEBI:76612"}],"text":"With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}

{"project":"2_test","denotations":[{"id":"32572532-29437588-47963395","span":{"begin":113,"end":114},"obj":"29437588"},{"id":"T15892","span":{"begin":113,"end":114},"obj":"29437588"}],"text":"With changing treatment modalities, new risk groups continue to emerge, such as patients treated with ibrutinib [4, 5]."}